heart liver News
-
Creative Medical Technology Announces Progress in Developing a Reproducible Clinical Grade of the Company`s ImmCelz Product
Creative Medical Technology Holdings, Inc. ("Creative Medical Technology" or the "Company") (NASDAQ: CELZ), a leading commercial stage biotechnology company focused on a regenerative approach to immunotherapy, urology, neurology, and orthopedics, today announced progress in developing a reproducible clinical grade product of ImmCelz®. Multiple clinical experiments were performed in which the ...
-
CELLINK and the University of California, San Diego Partner to Open a 3D Bioprinting Centre of Excellence
CELLINK, a leading global provider of bioprinting technologies, and the University of California, San Diego (UCSD), a world-renowned research institution, are pleased to announce their partnership to establish a 3D bioprinting Centre of Excellence. This partnership aims to facilitate the utilization of advanced bioprinting technologies and promote cutting-edge research in the fields of drug ...
By CELLINK
-
Adult Stem Cells
Adult stem cells are undifferentiated cells, found throughout the body after embryonic development, which multiply by cell division to replenish dying cells and regenerate damaged tissue. Adult stem cells support tissue and organ turnover throughout life by maintaining a delicate balance between apoptosis and tissue-specific cellular proliferation and differentiation. Adult stem cells reside ...
-
ViGeneron presents preclinical data on intravitreal gene therapy of Stargardt disease at ESGCT
Efficient transfer of larger gene via ViGeneron’s proprietary technology platforms REVeRT and vgAAV ViGeneron advances its preclinical programs for Stargardt disease and Retinitis Pigmentosa into IND-enabling activities and clinical stage development ViGeneron GmbH, a next-generation gene therapy company, today announced the presentation of preclinical data on its program VG801 in ...
-
National food and drink manufacturing conference
If you work in the food & drink industry and have come into contact with Peracetic Acid, have you ever suffered from health effects? Peracetic acid (PAA) is a hazardous sterilant used in the food and drink industries. When people are exposed to it for periods of time, PAA can be very dangerous. Over exposure to PAA can cause severe physiological effects including: Irritation and burning of ...
-
Creative Medical Technology Signs Master Collaboration Agreement with the University of Miami to Accelerate Development of ImmCelz Supercharged Autologous Immunotherapy Platform
Creative Medical Technology Holdings, Inc. ("Creative Medical Technology" or the "Company") (NASDAQ: CELZ), a leading commercial stage biotechnology company focused on a regenerative approach to immunotherapy, urology, neurology, and orthopedics, today announced that it has signed a Master Collaboration Agreement with the University of Miami to accelerate development of the Company's ImmCelz® ...
-
Alexandra Clyde appointed to Sequana Medical Board of Directors
Sequana Medical NV (Euronext Brussels: SEQUA) (the “Company” or “Sequana Medical“), a pioneer in the treatment of drug-resistant fluid overload in liver disease, heart failure and cancer, today announces the appointment of Alexandra Clyde as an independent Non-Executive Director of the Company. Ms. Clyde is a highly experienced global business executive with an exceptional ...
-
Creative Medical Technology Holdings Announces Agreement with Greenstone Biosciences, Inc. for Development of a Next Generation iPSC Pipeline for its ImmCelz Immunotherapy Platform
Creative Medical Technology Holdings, Inc. ("Creative Medical Technology" or the "Company") (NASDAQ: CELZ), a leading commercial stage biotechnology company focused on a regenerative approach to immunotherapy, urology, neurology, and orthopedics, today announced that the Company has signed an agreement with Greenstone Biosciences Inc. in Palo Alto, CA for the development of a human induced ...
-
Expand Your Diagnostic Capabilities with Vimago HDVI and Save $$$$ Through Section 179 Tax Deduction
Applications HD 3D imaging technology used in the Vimago system provides a solid volume of data, resulting in gapless, non-interpolated imaging data, delivering a 3D map of densities with spatial resolution that is the same in all three dimensions. Hard Tissue Applications: Skulls - sinus, nasal, bulla, ears, brain, oncology, trauma Orthopedics - stifles, elbows, hips, carpus/tarsus, ...
-
Sequana Medical secures EUR 10 million loan facility with Kreos Capital
Sequana Medical NV (Euronext Brussels: SEQUA) (the “Company” or “Sequana Medical“), a pioneer in the treatment of drug-resistant fluid overload in liver disease and heart failure, today announces it has entered into a secured loan facility agreement of EUR 10 million with Kreos Capital VI (UK) Limited (“Kreos”). Proceeds from the loan will be used to finance ...
-
IAQ Marketing Specialist Reveals his Personal Fight with Mold
A fungal infection caused by Coccidioides immitis, also known as Valley Fever, took its toll on Paul Cochrane, President of Cochrane & Associates, LLC. In the October 2010 issue of Indoor Environment Connections a personal story of one of the industry’s own is detailed in an article entitled, “A Fungal Infection of the Lungs”. The article details the story of the ...
-
Creative Enzymes Introduces a New Line of Coenzyme Products for the Supplement and Pharmaceutical Industries
Creative Enzymes, a professional enzyme provider located in New York, USA, is always hammering away at research and trials in order to provide customers with as many enzyme services and products as possible. The company recently launched a series of coenzyme products for the supplement industry and pharmaceutical industry. A coenzyme is a small organic molecule, but not a peptide, which binds ...
-
PharmAbcine Signs MoU with FutureChem to Explore Possibilities of Developing Novel Radiopharmaceuticals
PharmAbcine Signs MoU with FutureChem to Explore Possibilities of Developing Novel Radiopharmaceuticals PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of next-generation antibody therapeutics, announced today that it signed an MoU (Memorandum of Understanding) with FutureChem Co., Ltd. (“FutureChem”) (KOSDAQ: 220100ks), a leading ...
-
Doug Kohrs appointed to Sequana Medical Board of Directors
Sequana Medical NV (Euronext Brussels: SEQUA) (the “Company” or “Sequana Medical“), a pioneer in the treatment of drug-resistant fluid overload in liver disease and heart failure, today announces the appointment of Doug Kohrs as an independent Non-Executive Director of the Company. Mr. Kohrs is a highly experienced US executive with a track record of more than 40 years in ...
-
Discover our top-selling Precellys kits!
For many years, scientists all around the globe have been using Precellys lysing and grinding kits, as they have been proven efficient and safe in a broad range of research areas including microbiology, pharmacology, cancer, forensic medicine, the environment, and even agronomy. Here below, discover our top three bestselling kits and find the perfect solution for your sample prep! ...
-
Ultravist by Bayer now approved for contrast-enhanced mammography in EU
Ultravist-300, -370 receives green light for indication extension for use in contrast-enhanced mammography (CEM) in a European Workshare Procedure CEM is emerging modality combining digital mammography with the administration of a contrast agent Strategically expands Bayer’s portfolio in breast imaging, including contrast agents and injectors Bayer announced today that its ...
By Bayer AG
-
Reprise Biomedical Completes Spin-off from Miromatrix Medical
Reprise Biomedical, Inc., a Minnesota-based startup focused on commercializing biological medical devices manufactured using a proprietary perfusion decellularization technology, has successfully completed a $12.5 million private placement and commenced operations as a spin-off from Miromatrix Medical Inc. Through the spin-off, Miromatrix transferred to Reprise two existing FDA 510(k) cleared, ...
-
Poietis signs a clinical research collaboration contract with the Assistance Publique – Hôpitaux de Marseille (AP-HM) to prepare the first clinical trial of a bioprinted skin.
Poietis, leading bioprinting company, and the « Assistance Publique – Hôpitaux de Marseille » (AP-HM) announced today that they have entered into a partnership through the signature the 20th of January of a clinical research collaboration contract on a bioprinted tissue engineering product. The objective of this agreement is to carry out within two years a Phase I clinical ...
By Poietis
-
Union Leader: Millyard lab will be used to manufacture human tissue for clinical trials
It’s been nearly five years since Dean Kamen announced the launch of BioFabUSA, a program of the Advanced Regenerative Manufacturing Institute to jump-start the large-scale production of synthetic human tissue. Under the direction of Chief Technology Officer Tom Bollenbach, BioFabUSA has created a “tissue foundry” as a working prototype to manufacture cells, which ...
-
Sequana Medical completes enrollment in Phase 2a SAHARA I DSR study, reports disease-modifying profile for Short Term DSR and provides business update
DSR (Direct Sodium Removal) heart failure drug development: Completed enrollment in SAHARA I[i] with first-generation DSR product (“DSR 1.0”) – extending study with second-generation DSR product (“DSR 2.0”) to support US IND[ii] filing by year end Proof-of-concept delivered in diuretic-resistant heart failure patients with dramatic and durable improvements in ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you